List of researchers signaling their interest in joining the Canadian Consortium on Neurodegeneration in Aging (CCNA)

Name/Title/ Research Institution/ Organization	Website	Areas of expertise relevant to the CCNA	Areas of research interests within the scope of the scope of the call
Patricia McKinley, Associate Professor, McGill University School of Physical and Occupational Therapy	School of Physical & Occupational Therapy, McGill University	Motor control, kinesiology, exercise physiology, activity analysis, social interaction.	Leisure based activities that promote mental and physical health and well being in vulnerable populations.
Heather Keller, Schlegel Research Chair Nutrition & Aging, Professor, Schlegel-Waterloo Research Institute for Aging, Applied Health Sciences, University of Waterloo	Dr. Heather Keller's website	Nutrition risk screening, nutrition/dietary assessment. Nutrition interventions to promote weight maintenance/nutritional status in persons with dementia. Mealtime interventions to promote quality of life for persons with dementia. Qualitative and quantitative methodological expertise. Using qualitative methods, conducted a 6-year longitudinal study with persons with dementia and their primary family care partners, on the experience and meaning of mealtimes. This leads to the development of the Life Nourishment theory which identifies that beyond nutrients and pleasure with eating, mealtimes provide a sense of belonging and connection as well as honouring of identity that supports the quality of life of persons with dementia and their family partners in care.	Primary prevention: promotion of healthy eating in late middle-age and older adults to promote nutritional status, reduce sarcopenia and maintain healthy body weight. Secondary prevention: promotion of quality diet and modification of risk factors that can impair food intake post identification of MCI or early stage dementia with the goal of maintaining nutritional status to delay progession and assist care partners with coping. Using mealtimes as a focus for continuity of identity and roles. Quality of life: the importance of food to well-being beyond nutrients. Specifically how the mealtimes can promote connection and honour identity, thus promoting improved quality of life. Promotion of person-centred care with respect to meals in residential homes.
Marco A.M. Prado, Professor and Scientist, Robarts Research Institute	Marco Antonio Maximo Prado, Robarts Research	Generation of genetically-modified mice, animal models of Alzheimer's; behavioral analysis; cell signaling in Alzheimer's disease; biology of the prion protein; prion diseases, cognitive function; dementia and cholinergic function.	Animal models of Alzheimer's disease; drug development and high throughput behavioral testing; toxicity of Abeta peptides; novel pharmacological strategies in Alzheimer's disease.
Minh Dang Nguyen, Associate Professor, University of Calgary, Hotchkiss Brain Institute	University of Calgary, Hotchkiss Brain Institute	Neurodegeneration, aging, cytoskeleton, cell signaling, molecular/cellular biology, mouse models.	Primary prevention through the elucidation of mechanisms underlying neurodegenerative disorders with cognitive deficits. My laboratory has generated a unique new mouse model with synaptic and dendritic pathologies reminiscent of neurodegenerative disorders with cognitive dysfunction (unpublished). By characterizing this mouse model we may identify new targets and strategies for the prevention of these diseases.
Sheila Novek, PhD student, Department of Community Health Sciences, University of Manitoba	Email: umnovek@ cc.umanitoba.ca	Dementia care and quality of life. Early-onset dementia. Nursing home care. Long-term care human resources. Immigrant care workers. Care transitions. Family caregiving. Qualitative health research methods.	I will be commencing the PhD program in the Department of Community Health Sciences at the University of Manitoba in September 2013. For my dissertation, I plan to conduct a mixed methods study examining the care pathways and health service needs of people with early-onset dementia across the continuum of care. I am interested in participating in the quality of life theme. Specifically, I am interested in contributing to research related to dementia care, access to care, long-term care, family caregiving, and research involving minority populations with dementia (e.g., young people, ethnic minorities, Aboriginal Peoples, and people with intellectual disabilities).
Alok S Tripathi, P. Wadhwani College of Pharmacy, Yavatmal (MS) India 445001		Diabetic complications, bioanalysis, drug interaction studies.	Diabetic complications.
Gerlinde A. Metz, Dr. Sc. nat. habil., Professor of Neuroscience, AHFMR Senior Scholar, Canadian Centre for Behavioural Neuroscience, University of Lethbridge	Metz Behavioural Neuroscience Lab	Parkinson's disease, stroke, multiple sclerosis, animal models, neurofunctional assessment, environmental risk factors, prediction, epigenetics, perinatal determinants, aging, transgenerational programming, knowledge translation.	Networking and collaboration in assessing the neuropathological processes of Parkinson's disease, multiple sclerosis, stroke and others; knowledge translation; improvement of animal models; behavioural test strategies; epigenetic profiling.
Gregory Fairn, Staff Scientist and Assistant Professor, St. Michael's Hospital, Department of Surgery, University of Toronto	St. Michael's Hospital, Keenan Research Centre	Single cell microscopy, lipidomics, signal transduction, phagocytosis, endocytosis, innate immunity, vesicular trafficking, lysosomal maturation, TIRF.	Scavenger and apoptotic body receptors in the brain and CNS, their role in tissue homeostasis and regulating the balance between pro- and anti-inflammatory signalling in the aging brain and after brain injury. Cellular lipidomics and membrane nanodomains/lipid rafts. The sub-compartmentalization of cellular membranes is important for cellular function. Yet, their presence and functionality likely decrease during aging and neurodegenration. Oxidatively modified lipids and their impact on endocytosis, phagocytosis and the degradative capacity of the lysosomes.
Anne Dull Baird, PhD, Associate Professor, University of Windsor	University of Windsor, Centre for the Study of Cognition and Function across Adulthood	Clinical neuropsychological assessment of older adults.	Collaborative therapeutic neuropsychological assessment of older adults, as a way of promoting healthy adjustment in those with and without cognitive impairment and as a basis for intervention-facilitating function in older adults with and without cognitive dysfunction -preventing cerebrovascular disease and promoting recovery from stroke as a way of reducing risk for manifestation of Alzheimer's disease.
William Jia, Associate Professor and Investigator, Brain Research Centre, UBC		Molecular virology virus, mediated gene therapy, TDP-43 cell biology, drug discovery from natural products.	TDP-43 proteinopathies Progranulin Neuroprotection and cognitive enhancement by natural products.
Jalila Jbilou, Chercheure Professeure associée, Unité de médecine familiale de Dieppe-Réseau de santé Vitalité, Centre de formation médicale du NB, École de psychologie, Université de Moncton.		Transfert de connaissances. Collaboration synergique entre santé publique et services cliniques de 1ère ligne. Organisation des services de santé. Cybersanté.	Prévention secondaire. Qualité de vie.
Dr. William J. Tippett, Assistant Professor, University of Northern British Columbia	University of British Columbia, Brain Research Unit	Alzheimer's disease, aging, stroke, rehabilitation, neuroscience, cognitive decline, mild cognitive impairment.	Cognitive rehabilitation, diagnosis, treatment intervention including physical and mental.
Anne Robichaud, chercheure autonome		Doctorat en psychologie.	Travaille avec une équipe de psychiatres français sur le dépression, la motivation et la démotivation.
Benedict Albensi, Everett Endowment Fund Chair, Associate Professor of Pharmacology & Therapeutics, Adjunct Professor of Electrical & Computer Engineering, Principal Investigator, St-Boniface Research Ctr., University of Manitoba	St-Boniface Hospital, Division of Neurodegenerative Disorders	Aging Alzheimer's disease. Memory decline and memory impairments. Seizures and epilepsy. Head trauma and stroke. Electrophysiology MRI. Cell/molecular assays, behavioural tests for memory.	Transcriptional regulation of memory, calcium hypothesis of Alzheimer's disease, mitochondrial dysfunction, CREB and NF-kB signaling neonatal risk factors for chronic brain disease, nutritional intervention for CNS disorders, creatine Choline electrical stimulation, AKA, deep brain stimulation.
Angeles Garcia, MD, PhD, FRCPC Professor Medicine & Neuroscience, Queen's University		Alzheimer's dementia & cognitive aging. Functional MRI of selective attention, volumetric determinations, DTI, tratography. Telomere 3D architecture analysis. Clinical trials for AD. Neuropsychological testing. Saccadic eye movements. Clinical diagnosis of AD and MCI.	All aspects of cognitive changes with aging. Imaging: fMRI, DTI-tractography, volumetry. Early AD diagnosis and new treatments for AD and MCI. New non-invasive diagnostic methods: 3D telomere analysis.
Eleftherios P. Diamandis, MD, PhD, FRCPC, FRSC ACDC laboratory, Samuel Lunenfeld Research Institute, Mount Sinai Hospital (Toronto)	Advanced Center for Detection of Cancer, Laboratory of Eleftherios P. Diamandis	Proteomics/ Mass spectrometry/ Post-translational modifications/ Alzheimer’s disease.	Our laboratory has great expertise in cancer biomarker research. We have discovered several cancer biomarkers; including the kallikrein family (please visit our website for more details). Recently, we have ventured in to Alzheimer's disease research and our first study was the quantitative proteomic analysis of human hippocampal tissues from Alzheimer’s disease patients and age-matched controls (Begcevic et al., Clinical Proteomics 2013; accepted for publication). Using state-of-the-art mass spectrometry tools and proteomics, we are now studying different post-translational modifications (palmitoylation and lysine acetylation) in brain tissue extracts from patients with Alzheimer’s disease. We believe that aberrations of these post-translational modifications may play an important role in the onset and progression of the disease. Lysine acetylation is a post-translational regulatory mechanism, which modulates protein activity and initiates cross talk with other post-translational modifications for dynamic control of cellular signaling. Mounting evidence in recent literature suggests that alterations of this epigenetic modification (lysine acetylation of tau protein) are associated with neurodegenerative diseases, including Alzheimer’s disease. On the other hand, palmitoylation appears to play a significant role in subcellular trafficking of proteins between membrane compartments as well as in modulating protein-protein interactions. This post-translational mechanism seems to be important in synaptic plasticity and neuronal development. Given that synapses are damaged early during the neurodegenerative processes of Alzheimer’s disease, they could be a prime source of impaired palmitoylated proteins and reveal mechanisms of neurodegeneration. The identification of proteins with altered pattern of palmitoylation and/or lysine acetylation during the evolution of the disease may lead to find therapeutic targets to prevent the appearance or the development of Alzheimer’s disease as well as the delay of clinical manifestations. Furthermore, we have also developed a mass spectrometry-based method for the identification and quantification of Apolipoprotein E isoforms in cerebrospinal fluid and plasma samples, which provides relevant information in the study of these patients.
Douglas Munoz, Professor and Director, Centre for Neuroscience Studies, Tier I Canada Research Chair in Neuroscience, Queen's University	Queen's University, Queen's Eye Movement Laboratory	Monkey model of Alzheimer's disease, monkey model of Parkinson's disease, combining eye tracking and functional imaging to study cognitive abnormalities in Parkinson's, Alzheimer's, mild cognitive impairment, amyotrophic lateral sclerosis, Tourette, Huntington's. Eye tracking behavioural neurophysiology, awake monkey neurophysiology, computational modeling of disease impact on eye movement circuit.	Monkey model of Alzheimer's disease, monkey model of Parkinson's disease. Combining eye tracking and functional imaging to study cognitive abnormalities in Parkinson's, Alzheimer's, mild cognitive impairment, amyotrophic lateral sclerosis, Tourette, Huntington's. We are developing monkey models of neurodegenerative disorders so we can study the molecular, systems, behavioural, and imaging effects of the disease and the effectiveness of any treatment intervention. The monkey experiments are done in parallel with human clinical studies using the same behavioural paradigms.
Eric Rassart, Apolipoprotein D as a neuroprotective and repair protein in neurodegenerative disorders, Université du Québec à Montréal	Dr. Rassart, Université du Québec à Montréal	Neurodegenerative diseases, Alzheimer, multiple sclerosis, Parkinson, stroke, neuroprotection, repair, molecular and cellular biology, animal models.	Human Apolipoprotein D (ApoD) is a 29-kDa secreted glycoprotein and a lipocalin carrying several small hydrophobic molecules. It is expressed at high levels in several tissues particularly in the central nervous system (CNS) where it is produced in glia but also in scattered neurons. Its expression is increased in several neuropathologies such as Alzheimer’s, meningoencephalitis, stroke, Parkinson’s, Niemann-Pick’s type C and multiple sclerosis. ApoD expression and cell proliferation are inversely correlated in response to cellular stress. Despite several putative roles attributed to ApoD such as repair and reinnervation as well as lipid turnover after nervous tissue injury, the precise role of ApoD in the CNS remains elusive. However, transgenic and KO animal models, accumulating evidences suggest that apoD plays a neuroprotective role as a repair protein.
Machelle Wilchesky, Assistant Professor, Division of Geriatric Medicine, McGill University, Lady Davis Institute for Medical Research, Jewish General Hospital, and Donald Berman Maimonides Geriatric Centre	Donald Berman Maimonides Geriatric Centre	Geriatric pharmacoepidemiology, long-term geriatric care.	Secondary prevention and quality of life.
Theresa Green, RN, PhD Associate Professor Faculty of Nursing, University of Calgary	Dr. Theresa Green, University of Calgary	Dementia care and quality of life. Early-onset dementia. Transitions across the care trajectory. Family caregiving & caregiver burden/outcomes - living with dementia. Mixed methods studies: quantitative & qualitative health research methods. Stroke recovery and reintegration to community.	Access to care and services - with an interest in ethnic and gender differences in access to care and services. Rural and urban populations. Family-centred care and quality of life. Advanced care planning and palliative care in the context of stroke and dementia.
Tiina M. Kauppinen, Assistant Professor, Dept. of Pharmacology and Therapeutics, University of Manitoba and Group leader in Mental Health and Neurodegeneration Research Program, Kleysen Institute for Advanced Medicine, Dept. of Pharmacology and Therapeutics, University of Manitoba and Kleysen Institute for Advanced Medicine	Dr. Tiina Kauppinen, University of Manitoba	Neuroinflammation, microglia, astroglia, neurodegeneration, Alzheimer's disease, ischemic stroke, cell signaling, cell culture models of neurodegeneration.	Regulation of inflammatory responses, NF-kB signaling, the role of PARP-1 as a modulator of inflammatory responses, development of anti-inflammatory approaches in neurodegenerative disorders, Alzheimer’s disease, ischemic stroke, post-traumatic dementia, sex differences in response to therapies.
Kristen Jacklin, PhD Associate Professor, Medical Anthropology, Northern Ontario School of Medicine	Kristen Jacklin, Northern Ontario School of Medicine	Age-related dementias in Aboriginal people; cultural perceptions of Alzheimer’s disease and related dementias in Aboriginal peoples; Aboriginal health systems and policy; international Indigenous dementia research networks; community-based Aboriginal health research; culture and healthcare; cross-cultural medicine and cultural safety; chronic disease in Aboriginal populations.	National and international research collaborations in age-related dementia in Indigenous populations: In 2009, I founded and continue to lead the International Indigenous Dementia Research Network (IIDRN) in order to promote research concerning age-related dementia in Indigenous populations. This existing network can be accessed to engage appropriate researchers (nationally and internationally) and community partners to participate in an Aboriginal focused research program (team) within the CCNA. Our growing network consists of established Indigenous and non-Indigenous scholars, community and organizational partners, new investigators and trainees from Canada, United States, Australia and New Zealand. Aboriginal quality of life research on age-related cognitive decline and impairment: I envision a research program that allows for cross-fertilization between Western and Indigenous understandings of age-related neurodegenerative illness. Specific areas of interest in the context of dementia include: Indigenous culture as medicine – especially traditional roles of elders, traditional language use, ceremony and teachings; respectful methods to combine biomedical and Indigenous knowledge systems in dementia care; access to culturally safe and appropriate care and resources – especially culturally appropriate cognitive screening protocols; Indigenous community care giving models; and, addressing the complexity of dementia care in Aboriginal communities – especially geographic isolation, high rates of complex co-morbid illness, and jurisdictional barriers to care.
Rona K Graham, Assistant Professor, Canada Research Chair in Neurodegenerative diseases, Université de Sherbrooke	Rona K Graham, Université de Sherbrooke	Alzheimer disease, Huntington disease, aging, molecular neurobiology, genetics, cell death pathways (apoptosis, caspases), excitotoxicity, inflammation, interactomes, behavior and neuropathology in mouse models, in vitro models.	Therapeutic approaches for Alzheimer disease and Huntington disease. Defining underlying molecular mechanisms involved early in the pathogenesis of neurodegeneration with a focus on excitotoxicity and caspases. Behavioral and neuropathological characterization of models of neurodegeneration. Development of AD mouse models replicating key behavioral and neuropathological features observed in human AD. Assessing therapeutic approaches (compounds, genetic knockouts, knockdown) and behavior (environmental enrichment studies) in models of neurodegeneration.
Réjean Plamondon, Professeur, École Polytechnique de Montréal	Réjean Plamondon, École Polytechnique de Montréal	Modélisation neuromotrice.	Études sur le vieissement et les risque d'accidents vasculaires cérébraux. Woch, A., Plamondon, R., O’Reilly, C., “Kinematic Characteristics of Successful Movement Primitives in Young and Older Subjects: a Delta-Lognormal Comparison”, Human Movement Science, No 30, No.1, pp. 1-17, 2011. O’Reilly, C. Plamondon, R. “Impact of stroke risk factors on Human Movements”, Human Movement Science, No 30, No.4, pp.792–806, 2011. O’Reilly, C., Plamondon, R., “A Lognormal Framework for Human Movement Rehabilitation”, Chapitre 19 du livre “Rehabilitation Engineering”, Tan Yen Kheng Ed., INTECH Publishing, ISBN: 979-933-302-023-0, pp. 157-172, Décembre 2009. Disponible en ligne. O’Reilly, C., Plamondon, R., Design of a Neuromuscular Disorders Diagnostic System using Human Movement Analysis, Proc. 11th Int. Conf. on Information Science, Signal Processing and their applications, (ISSPA), Montréal 3-5 Juillet 2012, pp. 787-792.
Jiming Kong, Professor, Department of Human Anatomy and Cell Science, University of Manitoba	Dr. J. Kong, University of Manitoba	Molecular pathways of neuronal cell death in neurodegenerative diseases. Established research collaboration with neuroscience researchers in China.	Role of post-translational modification of SOD1 in the formation of protein aggregates in ageing-related neurodegenerative diseases. Development of inhibitors for the BNIP3 cell death pathway, which is involved in neurodegenerative diseases.
Tony Szturm, PT, PhD Associate Professor, School of Medical Rehabilitation, University of Manitoba		Expertise: rehabilitation, neuroscience and biomedical engineering. My research is multidisciplinary and includes design, development and validation of technology-assisted rehabilitation platforms, therapeutic gaming and cognitive enrichment tools and approaches that provide a personalized, blended approach to decline in balance, mobility, vision, and cognition.	Research includes development and examination of interventions with embedded assessment (automated monitoring) of: core balance skills, mobility skills, gaze control and visuo-spatial attention, executive cognitive function (processing speed, working memory, cognitive inhibition), dual tasking (interaction of physical demands and cognitive, fall risk). Multi-task training paradigms that simultaneously address both mobility, vision, and cognition will benefit healthy aging and are important to consider in rehabilitation. Using a computer-based platform one can objectively quantify duration and intensity of both exercise and cognitive activity. Performance can also be quantified, trend analysis can be conducted, and dose–response relationships established. Develop and validate low-cost, engaging exercise and cognitive platforms with automated monitoring tools that can extend quality health care to the community and ultimately the home.
Praveen P Nekkar Rao, Assistant Professor, School of Pharmacy, Health Sciences, University of Waterloo	Laboratory of Medicinal and Bioorganic Chemistry, University of Waterloo	Design of small molecules to understand the mechanisms of neurodegeneration associated with cholinergic, amyloid, tau and oxidative stress pathways in Alzheimer's disease. Developing small molecules as diagnostic agents to detect neurodegeneration.	Primary prevention by discovering key interactions involved in cholinesterase inhibition, amyloid and tau-aggregation. Developing hybrid molecules to target multiple neurodegeneration mechanisms as opposed to traditional "one drug, one target" approach. Our lab has expertise in synthetic medicinal chemistry, computational chemistry, cholinesterase inhibition assays, amyloid/tau-inhibition screening and transmission electron microscopy. We have discovered novel small molecules as potential disease-modifying neurotherapeutics. Other potential application include development of novel molecules as diagnostic agents for early detection of neurodegeneration.
Denise Cloutier Fisher, Associate Professor, Department of Geography and Centre on Aging, University of Victoria	Denise Cloutier, University of Victoria	Mixed and multiple research methods, rural environments, longitudinal studies, transitions in care (in the institutional sector).	The service continuum for seniors (acute care to community-based care alternatives). Special issues of rural populations. Environments for aging.
Wayne Warry, Director and Professor, Centre for Rural and Northern Health Research, Laurentian University	Wayne Warry, Centre for Rural and Northern Health Research	Dementias in Aboriginal/Indigenous peoples; cultural perceptions of Alzheimer’s disease and related dementias in Aboriginal peoples; Aboriginal health systems and policy; rural and remote health care; community based and participatory research.	Aboriginal quality of life research on age-related dementia. The Centre for Rural and Northern Health Research (CRaNHR) at Laurentian University is engaged in research with vulnerable populations, including Aboriginal, Francophone, rural and remote populations, and specifically research concerning chronic conditions including dementia in Aboriginal communities. CRaNHR is also engaged in the Ontario-CIHR Strategy for Patient Oriented Research and is well placed to facilitate research on telehome care, and other innovative patient centred initiatives that might impact on the quality of life for Aboriginal and mainstream seniors with dementia in rural and remote areas. I am part of International Indigenous Dementia Research Network led by Dr. Kristen Jacklin at the Northern Ontario School of Medicine, and an Aboriginal health researcher with extensive experience in Aboriginal community engagement. I would be interested in assisting with the development of “two-eyed seeing” approaches to research and knowledge translation concerning dementia in Indigenous populations nationally and internationally.
Md. Golam Sharoar, Dept. of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi 6205, Bangladesh.	Dept. of Genetic Engineering and Biotechnology, University of Rajshahi	Aggregation mechanism of Alzheimer's. Amyloid beta peptide, it's cytotoxic effects and its inhibition by small molecules and protein. Interaction of Amyloid beta with intra- and extra- cellular proteins. Apoptosis. Purification of recombinant amyloid beta peptide.	I have obtained Canada immigration and wishing to involve in a university/institute in Canada as a postdoctoral fellow in the areas of neurodegenerative disorder, misfolded protein aggregation mechanism and disease development, interaction mechanism of amyloid beta with intracellular proteins in developing Alzeimer's disease.
Julie Nantel, Professeure Adjointe/ Assistant Professor, École des sciences de l'activité physique/School of Human Kinetics, Faculté des sciences de la santé/Faculty of Health Sciences, Université d'Ottawa/University of Ottawa	Julie Nantel, University of Ottawa	Mild Cognitive Impairment, postural impairment and gait disturbances. Parkinson's disease, normal and pathological aging. Freezing of gait, biomechanics, movement analyses, rehabilitation and neurorehabilitation and mobility.	Secondary prevention and quality of life: improvement of techniques to detect and measure mild cognitive impairment, postural instability, gait deficits and their relationships. Development of intervention modalities (cognitive and motor) to reduce symptoms and improve mobility. Promotion of an active lifestyle and measuring the benefits on quality of life.
William Sheridan, Independent Scholar		Knowledge Policy - your interest in "knowledge translation" parallels my own. I have just completed a manuscript for a book to be titled how to present knowledge to the public. What I am proposing is that scientific jargon be "translated" into the popular idiom by Public Information Officers, so that new research results (on aging and anti-aging) can be communicated to the public through Knowledge News Releases, thereby enabling "the average person" to gain the benefits of the research. Anti-aging - I am on a personal "anti-aging campaign" to indefinitely prolong both my lifespan and my quality of life, in keeping with Ray Kurzweil's projection that, with the current rate of progress in the life sciences, the prospect of achieving "human immortality" is now foreseeable. I have developed my own "biochemical strategy" to pursue this objective.	I would like to collaborate with CCNA on further work on the "knowledge translation" front, because the same thinking that assists in translating research into applications, also is the basis for translating research into the popular idiom. Both need to be tacked in parallel. I would also like to collaborate on assessing existing or prospective "anti-aging strategies," to determine if certain supplements are or are not "the key to anti-aging." Many medical doctors and nutritionists claim, very confidently, that they have indeed discovered "the secrets to anti-aging." Is this just hype, OR is there some degree, perhaps a high degree of credibility to at least some of these claims? (It would be incredibly foolish to dismiss such claims out-of-hand just because they could not, at the moment, be supported by research data. It would be equally foolish to adopt any and all such claims, because many of them contradict many other of them. So how to proceed? Dare I suggest it, but the answer is "good judgment!")
Kaitlyn P. Roland, CIHR Post-Doctoral Fellow, Centre on Aging, University of Victoria	Centre on Aging, University of Victoria Kaitlyn P. Roland's web page	Parkinson's disease, dementia, caregivers, burden, well-being, daily physical activity (accelerometer, GPS), muscle function (electromyography), frailty, quality of life.	My research interests lie in supporting independence during daily living and improved quality of life in all persons living with Parkinson's disease and related dementias, including caregivers. Specifically, I hope to support physical function (muscle, exercise, yoga) in persons with Parkinson's disease and related dementia. Also, I aim to better understand caregiver needs, especially those caring for Parkinson's disease related dementia.
Michael E. Tschakovsky, PhD, Associate Professor, Human Vascular Control Laboratory, School of Kinesiology and Health Studies, Queen's University	Human Vascular Control Laboratory, Queen's University	Exercise, exercise training, cerebral perfusion, (cerebro)vascular control.	My primary research expertise is in exercise physiology, specializing in cardiovascular health and function as it relates to exercise. In collaboration with members of the Centre for Neuroscience Studies at Queen's University: I am now focusing this expertise on developing the application of exercise/physical activity approaches to protecting/improving cognitive function, brain structure and cerebrovascular health and function as we age. An important theme is the potential for synergistic benefits of exercise in conjunction with other potential therapeutic interventions such as cognitive training and dietary agents that have positive influence on cerebrovascular function.
David Chatenet, Assistant Professor, Institut national de la recherche scientifique, Centre INRS - Institut Armand-Frappier, Université du Québec, Réseau International des Instituts Pasteur	Institut national de la recherche scientifique	Pharmacochemistry, drug design, allostery, peptide chemistry, neurodegenerative diseases.	Conception of multivalent drugs for Neurodegenerative disorders. Development of allosteric modulators.
Joan Tranmer, PhD, Professor, School of Nursing and Community Health and Epidemiology, Queen's University		Health service and system research methods. Patient outcome measurement (including qualtiy of life and functional measures). Knowledge translation methodologies. Population based methodologies (i.e, use of administrative databases).	Prevention of degenerative diseases in both the primary care setting and in adulthood in the work setting (i.e., identifying persons at risk and modification of factors associated with risk). Optimization of quality of life and functional well being of older individuals with chronic degenerative conditions, and their caregivers. Optimization of health care system supports - across sectors of care (from hospital to home) and in a variety of settings, with a focus on the primary care setting and the nursing role.
Dr. Mark W. Rosenberg, Canada Research Chair in Development Studies, Professor of Geography, Professor of Public Health Sciences, Queen's University	Department of Geography, Queen's University	Health geography. Medical geography. Gerontology. Access to health services. Health systems analysis. Health Policy.	Population aging and quality of life. Access to health services related to aging. Access to imaging services.
Maria-Victoria Zunzunegui, Professor, Departement de médecine sociale et préventive, Université de Montréal, Centre de recherche du Centre Hospitalière de l'Université de Montréal (CRCHUM), Institut de research en sante publique de l'Université de Montréal (IRSPUM)	Maria-Victoria Zunzunegui, Centre Hospitalière de l'Université de Montréal Institut de research en sante publique de l'Université de Montréal	Epidemiology of aging, methods of longitudinal studies in population research, longitudinal data analysis.	Dementia and mild cogntiive impairment, screening in population based studies.
Louis Bherer, PhD, Neuropsychologue, Professeur titulaire, PERFORM Centre/Concordia University	PERFORM Centre, Concordia University	Prevention of cognitive decline. Physical exercise. Cognitive training. Intervention.	Bherer's research study the effect of cognitive stimulation and physical activity on cognitive decline associated with aging and chronic disease. Normal aging is often accompanied by declines in brain function that can harm the quality of life of seniors. However, not all people are affected in the same way and not all brain functions decline at the same speed. Louis Bherer and his team want to improve understanding of why and how intellectual stimulation and physical activity can help seniors maintain better brain functioning. He's also exploring whether these benefits are long lasting and are similar for seniors of all ages, sexes and health conditions.
Pierre Rainville, Professeur, Centre de recherche de l'Institut universitaire de gériatrie de Montréal, Université de Montréal	Dr. Pierre Rainville’s pain lab	Psychophysics, neuropsychology, psychophysiology and neuroimaging of pain and pain modulation in humans.	Effects of aging on the neural systems underlying pain and pain regulation.
Ingrid Johnsrude, Associate Professor, Canada Research Chair in Cognitive Neuroscience, Queen's University	Cognitive Neuroscience of Communication and Hearing, Queen's University	Cognition and aging, hearing and aging, speech perception and aging, knowledge-based perception and aging, neuropsychology, functional neuroimaging (fMRI).	Identification and exploration of experienced-based factors that can compensate for the impact on cognitive processing of neurodegeneration in aging.
Frederic Calon, Professor, Université Laval, Centre de recherche du CHU de Québec	Frederic Calon, Université Laval frederic.calon@crchul.ulaval.ca	Recherche sur la maladie d'Alzheimer. Modèle animaux (neuropathologie, comportement, etc.). Tissus post-mortem. Etude de la barrière hématoencépahlique.	Prévention primaire et prévention secondaire.
Tiago H. Falk, Assistant Professor, INRS-EMT, University of Quebec	Multimedia/Multimodal Signal Analysis and Enhancement (MuSAE) Lab	Multimodal neuroimaging, biomedical signal processing, neurotechnology, health diagnostics, data mining, machine learning, image processing, pattern recognition.	Very early diagnostics of Alzheimer's Disease (AD), objective treatment outcome measurement, automated AD progression monitoring.
Kaori Takehara-Nishiuchi, Assistant professor, Psychology, University of Toronto	Takehara Lab, University of Toronto	Alzheimer’s disease. Mild cognitive impairment. Rat model. Viral vectors. Tau. Behavioural analysis. Associative memory. Neurophysiology. Single neuron recording. Local field potentials. EEG. ERP.	My research is directed at examining pathophysiology of memory decline in early stage Alzheimer’s disease (AD). Through a collaboration, I have developed a rat model that accurately mimics a site-specific tau pathologies in early stage AD. By measuring activities of single and population of neurons while the model rat receives a memory task, I hope to identify alterations of brain activities that precede or accompany memory impairment. This study may form a link between a specific brain dysfunction and memory decline in AD. In doing so, it will help develop novel strategies for early detection and preventative care.
Fadi Massoud, MD FRCPC, Internist-Geriatrician, Associate Professor of Medicin, Department of Medicine, University of Montreal, Centre Hospitalier de l'Université de Montréal (CHUM) and Institut Universitaire de Gériatrie de Montréal (IUGM)	Centre Hospitalier de l'Université de Montréal (only in French)	Dementia care. Cognitive aging. Dementia.	Epidemiological studies. Early diagnosis of dementia. Clinical trials.
Tamas Fulop, Professeur, Universite de Sherbrooke, Centre de recherche sur le Vieillissement, Departement de Medecine, Service de Geriatrie	Research Centre on Aging	Cognition, immuno-inflammation, nutrition. Infections, cell signalling, oxidative stress, innate immunity, adaptive immunity. Inflammasome, apoptosis.	We are very much interested in the study of the role of immuno-inflammation in the pathogenesis and the clinical progression of dementia and other neurodegenerative diseases linked to age. We are also interested in the genetic and environmental (nutrition, infecftions, oxidative stress) factors related to neurodegenereascence and aging for the development and progression. The signalling in various immune cells related to the PAMP are of particular interests. The role of the inflammasome in neurodegeneresescence is also studied actuallly by us. Moreover, the anti-inflammatory treatments are also of major interests for our group.
Roger Lippé, Associate professor, University of Montreal	Dr. Roger Lippé, University of Montreal (only in French)	Cell biology, intra cellular transport, vesicular transport. Rab proteins.	Alzheimer, tau, propagation of tau, pathology.
Simona Maria Brambati, Professeur sous octroi, Département de Psychologie, Université de Montréal, Chercheuse, Centre de Recherche IUGM		Language, primary progressive aphasia, frontotemporal dementia, Alzheimer's disease, magnetic resonance imaging, aging, cognition.	Language deficits in neurodegenerative diseases and their anatomical correlates.
Dr Nandini Deshpande, Assistant Professor, Queen's University		Sensory functions, sensory integration, control of posture and gait, adaptive locomotion, mobility disability, fear of falling.	Sensory integration, control of posture and gait, adaptive locomotion, mobility disability, fear of falling.
Jennifer Walker, PhD Adjunct Assistant Professor, School of Public Health and Health Systems, University of Waterloo		Epidemiology of age-related dementias in First Nations, Inuit and Metis populations. Health-related quality of life research. Older adults’ use of health care services.	I have a specific interest in understanding the impact of age-related dementias on Aboriginal communities, families, and individuals and the associated social and health supports. I am a member of the International Indigenous Dementia Research Network led by Dr. Kristen Jacklin at the Northern Ontario School of Medicine.
Gwen Herrington, RN, BN, MN, Northern Health		1 year experience in locked unit with Alzheimer patients. 2 years on medical ward with Alzheimer patients a part of the patient population. 3 years experience as a liaison nurse. As liaison nurse I was often in contact with families coping with Alzheimer's as they were admitted to hospital.	I have recently graduated from the Master's program and am keen to be involved in research.
Edeltraut Kröger, BPharm, MSC, PhD, Adjunct professor, Faculty of Pharmacy, Université Laval, Researcher, Centre d'excellence sur le vieillissement de Québec (CEVQ), Responsable du regroupement sur les soins de longue durée du Réseau Québécois de Recherche sur le Vieillissement		Medication use among seniors with Alzheimer disease (AD) or related disorders: use of Quebec health administrative data to assess medication use, safety and effectiveness; optimisation and reduction of medication use among seniors with very advanced AD in long term care; improve medication adherence among seniors with early cognitive impairment living in the community. The methods applied are mostly epidemiology, pharmaco-epidemiology, knowledge syntheses, intervention planning and implementation, assessment of quality of care.	A particularly interesting topic may be a large randomized controlled trial to study patient specific outcomes with discontinuation of cholinesterase inhibitors in long term care patient with advances AD. Discontinuation of other medication having become inappropriate in advanced AD patients may be an additional topic. There is still uncertainty as to whether cholinesterase inhibitors actually delay nursing home placement in AD patients. Simultaneous analyses of several Canadian health administrative databases may further answer this question for the Canadian context. Unclear safety issues with these cholinergic medications could be answered at the same time.
Lise Talbot, Professeur titulaire, Centre de recherche sur le vieillissement de Sherbrooke, Centre de recherche Étienne LeBel		Prévention et promotion saine habitudes de vie, collaboration interprofessionnelle.	Prévention et promotion du déclin fonctionnel.
Dr. Carrie Bourassa, Associate Professor, Indigenous Health Studies, Inter-disciplinary Programs, Nominated Principal Investigator, Indigenous Peoples' Health Research Centre, University of Regina, First Nations University of Canada	Carrie Bourassa, First Nations University of Canada	Aboriginal women experiencing neurological conditions. Community-based Aboriginal health research and methodologies. Aboriginal health systems and policy. International Indigenous dementia research networks. Aboriginal end of life care. Creating culturally safe care in health service delivery for Aboriginal people and communities. Aboriginal women's health.	The impact of neurological conditions on Aboriginal women and their support networks. Specifically, I was the NPI on a competitively funded project by the Public Health Agency of Canada in partnership with the Native Women's Association of Canada that just ended March 31st. Employing Indigenous Community-based Research Methodologies, our team examined risk factors for neurological conditions, health care services utilized, and gaps in available services. The study pointed to a need for further research in a variety of areas and, in particular, the need for data. There is a lack of disaggregated Aboriginal specific neurologic health data. National and international research collaborations in age-related dementia in Indigenous populations: I am part of the International Indigenous Dementia Research Network (IIDRN) led by Dr. Kristen Jacklin in order to promote research concerning age-related dementia in Indigenous populations. This existing network can be accessed to engage appropriate researchers (nationally and internationally) and community partners to participate in an Aboriginal focused research program (team) within the CCNA. The growing network consists of established Indigenous and non-Indigenous scholars, community and organizational partners, new investigators and trainees from Canada, United States, Australia and New Zealand.
Stephen Scott, Professor, GSK-CIHR Chair in Neuroscience, Centre for Neuroscience Studies, Queen's University	Stephen Scott, Queen's University	Voluntary motor control using human and non-human primates. Use of robotics and other advanced technologies to quantify sensory, motor and cognitive function and dysfunction. Focus has been on assessment of subjects with stroke, but have expanded to examine typical development and aging and many other neurological disorders.	Use of robotics and other technologies to develop objective, automated behavioural tasks to quantify sensory, motor and cognitive function associated with healthy aging and with various neurodegenerative disorders.
Center for Advanced research in sleep medicine (12 researchers) including Drs Julie Carrier, JY Montplaisir, Ron Postuma, Jean-François Gagnon, Nadia Gosselin, Alex Desautels, J. Carrier, Scientific director, Center for Advanced Research in Sleep Medicine, Hôpital du Sacré-Coeur de Montréal, Institut Universitaire de Gériatrie de Montréal, Université de Montréal, McGill University, UQAM	Center for Advanced research in sleep medicine	Psychology, psychiatry, neurology. Sleep, sleep disorders, circadian rhythms, non-visual effects of light. Alzheimer, Parkinson, Lewy body dementia. Polysomnography, high density EEG, brain imaging (fMRI, PET, high resolution SPECT).	The link between sleep and brain plasticity in normal and pathological aging. Sleep as a prodrome of neurodegenerative diseases (mild cognitive impairment, Alzheimer, Parkinson, Lewy body dementia). Sleep apnea syndrome and cognitive impairments in the elderly. How non-visual effects of light may enhance vigilance and cognitive deficits in neurodegerative diseases?
Adriana Di Polo, Professor, Department of Pathology and Cell Biology, University of Montreal, Department of Neuroscience, University of Montreal (as of July 2013)	Adriana Di Polo, University of Montreal	Retina, optic nerve, neuronal death, neuroregeneration, retinal ganglion cell structure and function, inflammatory response, role of reactive glial cells in neural dysfunction, retinal degeneration, glaucoma, visual function, tau pathology, gene therapy, signaling mechanisms, siRNA-based neuroprotective therapies.	The retina is an intrinsic part of the central nervous system. As such, the retina undergoes important pathological changes during numerous neurodegenerative diseases. Recent studies demonstrate that amyloid beta lesions and tau aggregates appear first in the retina and later in the brain, indicating that early pathological changes in the retina could be used to predict onset and monitor progression of Alzheimer's disease. My laboratory has the expertise to use the retina for the development of novel diagnostic tools for early detection and follow-up of disease course. In addition, retinal imaging can be used to evaluate the efficacy of new therapeutics for this devastating disease.
Clive Baldwin, Canada Research Chair in Narrative Studies, Associate Professor of Social Work, St Thomas University	Clive Baldwin, St Thomas University	Prévention et promotion saine habitudes de vie, collaboration interprofessionnelle.	Prévention et promotion du déclin fonctionnel.
Véronique Provencher Ph.D., erg., Professeure, Université Laval, CHU de Québec, Centre d'excellence sur le vieillissement de Québec		Alzheimer Disease. Activity of daily living. Home safety. Risk assessment. Hospital discharge. Occupational therapy.	Safety at home following hospital discharge in older adults with dementia.
Xavier Roucou, Professor, Université de Sherbrooke	Xavier Roucou laboratory	Cellular biology of the prion protein. Prion diseases. Molecular connection between Abeta oligomers and the prion protein. Alternative proteins in prion diseases and spinocerebellar ataxia type 1. Apoptosis.	Toxicity of Abeta oligomers. Protein misfolding and aggregation. Proteomics and unconventional translation products. Molecular mechanisms responsible for the neurodegenerative processes that lead to Alzheimer's disease and other related dementias.
Danielle Laurin, Professeur titulaire, Centre d'excellence sur le vieillissement de Québec, Centre de recherche du CHU de Québec	Danielle Laurin, Université Laval (only in French)	Épidémiologie. Études basées sur la population. Facteurs de risque. Synthèse des connaissances. ECR.	Prévention primaire et secondaire. Démence/Maladie d'Alzheimer/Déclin cognitif. Marqueurs biologiques (inflammation, oxydation). Nutrition. Oméga-3. Contaminants environnementaux.
Debra Sheets, Ph.D., MSN, RN-BC, CNE, Associate Professor, School of Nursing and Centre on Aging, University of Victoria	Debra Sheets, University of Victoria	Family caregiving, dementia care and quality of life, long-term care, aging with disability, rehabilitation, assistive technologies to support independent living, community-based supportive services, transitions in care, quantitative methods, aging, disability and health policy.	I am particularly interested in research related to disability, dementia care and long-term care needs, particularly caregiving. I have also done work examining access to the continuum of community-based and long-term care, rehabilitative services and programs, supportive services and technologies for independent living, and knowledge translation.
Carole A Estabrooks, Professor & Canada Research Chair (Tier 1), University of Alberta	Knowledge Utilization Studies Program, University of Alberta Dr. Carole Estabrooks, University of Alberta	Knowledge translation, implementation science, improvement science, quality improvement, applied health services research, spread & scale-up of innovations, integrated KT (as a research approach).	Quality of care/quality of life for residents in the residential long term care system (60-80% of whom have a diagnosis of dementia). Quality of work life for direct care providers in residential LTC.
Emil F. Pai, Professor and Canada Research Chair in Structural Biology, University of Toronto, Campbell Family Cancer Research Institute	Emil F. Pai, University of Toronto	Molecular mechanisms of neurodegenerating diseases, Molecular mechanisms of protein misfolding. Structural biology with an emphasis on X-ray crystallography.	My lab works on the structural characterization of the molecular steps involved in the misfolding of proteins involved in neurodegeneration. This includes trapping misfolding intermediates by complex formation. Our focus so far has been on prion diseases and on ALS.
Kevin Woo, Assistant Professor, Queen's University		Wound care: self care, chronic disease management, diabetes. Pain management. Psychosocial Mental health: anxiety.	Wound care: self care, chronic disease management, diabetes. Pain management. Psychosocial Mental health: anxiety.
Jennifer J. Heisz, Assistant Professor, Department of Kinesiology, McMaster University	Jennifer J. Heisz's website	Exercise intervention. Cognitive training. Neuropsychological testing. Neuroimaging. EEG. Behavioural testing. Lifestyle assessment. Physical functional assessment.	Identifying neural biomarkers (e.g., EEG complexity) that predict susceptibility to neurodegenerative disorders in the preclinical period. Examining lifestyle interventions (e.g., exercise, cognitive training) that alter the trajectory of neurodegenerative disease progression in preclinical and clinical populations.
Wandong Zhang, MD., Ph.D, Adjunct Professor, Faculty of Medicine, University of Ottawa	Wandong Zhang, University of Ottawa Email: wzhan2@uottawa.ca	Altered lipid/cholesterol metabolism, ApoE4, and Alzheimer's disease. Altered insulin signaling and Alzheimer's disease. Molecular mechanisms of Alzheimer's neuroinflammation. Blood-brain barrier. Abeta transport, cerebrovascular inflammation, and Alzheimer's disease. Animal modeling of Alzheimer's disease and behavioral assessment.	Targeting ApoE4 for prevention and relief of Alzheimer's disease and vascular dementia. Targeting altered insulin signaling for prevention and relief of Alzheimer's disease and vascular dementia. Targeting neurovascular inflammation for prevention and relief of Alzheimer's disease and vascular dementia.
Dr. Christoph Borchers, Professor, Department of Biochemistry and Microbiology, Director, UVic–Genome BC Proteomics Centre, Don and Eleanor Rix BC Leadership Chair in Biomedical and Environmental Proteomics, University of Victoria	Genome British Columbia Proteomics Centre, University of Victoria	Proteomics, mass spectrometry, amyloidoses (Alzheimer's, Huntington's, ALS, Parkinson's, prions diseases), protein misfolding and aggregation using recombinant protein, post-translational modifications characterization and quantitation, quantitative proteomics, metabolomics, biomarker discovery.	Primary prevention: elucidating molecular mechanisms of disease through structural proteomics and characterization of disease-associated proteins (Tau and Abeta in Alzheimer's, SOD1 in ALS, alpha-synuclein in Parkinson's disease, huntingtin in Huntington's disease, prions in CJD and other prion diseases) and their aggregates. Identification of target epitopes for preventative treatments (e.g. vaccines) using structural proteomics to identify regions of protein where pathological interactions occur. Secondary prevention: development of novel diagnostics (proteomic, metabolomic biomarkers) for early detection of disease. Application of findings from structural proteomics studies to for rational design or identification of novel therapeutics to interfere with disease progression.
Holger Wille, Associate Professor, University of Alberta, Department of Biochemistry and Centre for Prions and Protein Folding Diseases	Holger Wille, University of Alberta	Protein misfolding diseases, mechanisms of protein aggregation, the structure of misfolded, disease-associated protein aggregates, biophysical analyses of misfolded protein aggregates.	The general focus of my work is the structure of amyloids and other disease-related, misfolded proteins. In particular, I am interested in the infectious prion protein (PrPSc) and the structure-function relationship underlying its infectious nature. In recent years, mounting evidence has implicated prion-like mechanisms in other neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Lou Gehrig’s disease. The mechanistic similarities and their molecular underpinnings represent interesting research avenues beyond the classical prion diseases.
Dr. Howard Chertkow, Professor of Neurology, McGill University, based at Lady Davis Institute, Montreal			Greetings: I am writing to provide an update on the status of our planned application to the Canadian Consortium on Neurodegeneration in Aging (CCNA)/CIHR. I am working with a large group (242 researchers to date) of the Canadian NDD research community to successfully respond to the call for LOIs (letters of intent) which is now termed “Expression of Interest” (EOI) by CIHR. In the proposal we are putting together, I will be the “Nominated Principal Applicant, NPA” and there will be three Theme Principal Applicants (Theme PAs): Theme 1 (Prevention), Jane Rylett (jane.rylett@schulich.uwo.ca), (assisted by David Hogan(dhogan@ucalgary.ca)) Theme 2 (Secondary Prevention), Sandra Black (sandra.black@sunnybrook.ca) Theme 3 (Quality of Life), Ken Rockwood (Kenneth.Rockwood@dal.ca) You are welcome to contact these people or myself to express interest in joining this initiative…and we will look at this list and contact people who fit into the teams we are building. Obviously, not everyone fits into a team and not everyone will be funded. And not every team proposed by us will be funded by CIHR either. Some researchers reading this, however, might indeed have been overlooked as we have organized rapidly. We are establishind cores (well, teams) within those theme areas: Theme 1: Genetics – Peter St. George-Hyslop Inflammation and Nerve Growth factors – Claudio Cuello Team Protein Misfolding – Neil Cashman Synapses and metabolomics – Jane Rylett Lipoproteins – Cheryl Wellington Exercise and lifestyle prevention factors – Carol Greenwood Theme 2 (Treatment Possibilities) Team: Vascular illness – Eric Smith Team: Parkinsonian features in dementia - Richard Camicioli Team: Developing new biomarkers in MCI and before - Roger Dixon Team: Cognitive Therapy and Rehabilitation - Sylvie Belleville Team: Behavioural Problems in Dementia - Nathan Hermann Team: Mobility and Cognition - Manuel Montero-Odasso Team: FTD - Robin Hsiung Theme 3 (Quality of Life) Team: Comorbidity and progression of dementia - Melissa Andrew Team: Gerontechnology support in dementia – Alex Mihailidis Team: Driving and dementia – Gary Naglie Team: Sensory and Cognitive Interface – Natalie Philips Team: caregivers and relieve their stress – Ken Rockwood Team: Health care system – Dr. Howard Bergman Team: Rural and Indigenous issues – Debra Morgan, Kristen Jacklin…
Joël Macoir, Professeur titulaire Chercheur, Université Laval, Centre de recherche de l'Institut universitaire en santé mentale de Québec	Joël Macoir, Institut universitaire en santé mentale de Québec (in French only)	Troubles du langage et de la cognition dans les maladies neurodégénératives dont les différentes variantes de l'aphasie progressive primaire, la maladie de Parkinson.	Approche comportementale des troubles du langage et de la cognition. Rééducation cognitive. Apport des nouvelles technologies pour le traitement et la compensation des troubles du langage et de la cognition dans les maladies neurodégénératives.
Mohamed Ali Al fakir, Faculty of Medicine, University of Damascus, Certificate of DIS (Diplome Interuniversitaire de Specialisation) in diagnostic radiology and medical imaging, 1994, Assistant Professor, Previous Chairman of Diagnostic Radiology and Medical Imaging Department, Radiologist	Email: alfakirscan@gmail.com	Magnetic resonance. Imaging Department at Strausburg 1994-1995. Magnetic resonance. Imaging Department at the university hospitals of Damascus University. Al-Sham Medical Imaging Center in Damascus (3tesla MRI).	One of Canadian university hospitals.
Kristine Newman, RN, CRN(C), PhD, Knowlege Translation Canada: Strategic Training Initative in Health Research, Post-Doctoral Fellow, Faculty of Health Sciences, School of Nursing, McMaster University		Rehabilitation nursing background with experience in Geriatric Rehab and Complex Continuting Care. Knowledge translation. Informatics. Evaluation of use of technology. Qualitative and quantitative methodologies.	Quality of Life of geriatric population with chronic degenerative conditions and their caregivers. Use of technologies to optimize quality of life and improve functioning of individuals with chronic degenerative conditions. Use of technologies to support caregivers of individual's with chronic degenerative conditions.